EP2459208A2 — Therapeutic agents for reducing parathyroid hormone levels
Assigned to Kai Pharmaceuticals Inc · Expires 2012-06-06 · 14y expired
What this patent protects
Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X 1 - X 2 - X 3 - X 4 - X 5 - X 6 - X 7 , wherein the X 1 subunit comprises a thiol-containing moiety and t…
USPTO Abstract
Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X 1 - X 2 - X 3 - X 4 - X 5 - X 6 - X 7 , wherein the X 1 subunit comprises a thiol-containing moiety and the distribution of charge on the X 2 -X 7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
Drugs covered by this patent
- Parsabiv (ETELCALCETIDE) · Kai Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.